About: Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice
Creator	Magrini, Stefano Alongi, Filippo Buglione, Michela Greco, Diana Guerini, Andrea Pasinetti, Nadia Spiazzi, Luigi Tomasini, Davide Triggiani, Luca Barbera, Fernando Bonometti, Nadia Bragaglio, Alessandra Costantino, Gianluca Liccioli, Mara Mascaro, Lorella Pegurri, Ludovica
Source	Medline; PMC
abstract	BACKGROUND: Coronavirus Disease 2019 (COVID-19) pandemic had an overwhelming impact on healthcare worldwide. Outstandingly, the aftermath on neoplastic patients is still largely unknown, and only isolated cases of COVID-19 during radiotherapy have been published. We will report the two-months experience of our Department, set in Lombardy “red-zone”. METHODS: Data of 402 cancer patients undergoing active treatment from February 24 to April 24, 2020 were retrospectively reviewed; several indicators of the Department functioning were also analyzed. RESULTS: Dedicated measures allowed an overall limited reduction of the workload. Decrease of radiotherapy treatment number reached 17%, while the number of administration of systemic treatment and follow up evaluations kept constant. Conversely, new treatment planning faced substantial decline. Considering the patients, infection rate was 3.23% (13/402) and mortality 1.24% (5/402). Median age of COVID-19 patients was 69.7 years, the large majority were male and smokers (84.6%); lung cancer was the most common tumor type (61.5%), 84.6% of subjects were stage III-IV and 92.3% had comorbidities. Remarkably, 92.3% of the cases were detected before March 24. Globally, only 2.5% of ongoing treatments were suspended due to suspect or confirmed COVID-19 and 46.2% of positive patients carried on radiotherapy without interruption. Considering only the last month, infection rate among patients undergoing treatment precipitated to 0.43% (1/232) and no new contagions were reported within our staff. CONCLUSIONS: Although mortality rate in COVID-19 cancer patients is elevated, our results support the feasibility and safety of continuing anticancer treatment during SARS-Cov-2 pandemic by endorsing consistent preventive measures.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1186/s13014-020-01631-2
bibo:pmid	32778174
has license	cc-by
sha1sum (hex)	421ee6a61562c1dfb4d9043639384a64d530c9ca
schema:url	https://doi.org/10.1186/s13014-020-01631-2
resource representing a document's title	Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice
has PubMed Central identifier	PMC7416803
has PubMed identifier	32778174
schema:publication	Radiat Oncol
resource representing a document's body	covid:421ee6a61562c1dfb4d9043639384a64d530c9ca#body_text
is schema:about of	named entity 'worldwide' named entity 'pandemic' named entity 'red zone' named entity 'PUBLISHED' named entity 'CORONAVIRUS DISEASE 2019' named entity 'NEOPLASTIC' named entity 'UNKNOWN' named entity '2019' named entity 'Coronavirus' named entity 'neoplastic' named entity 'impact' named entity 'red-zone' named entity 'Outstandingly' named entity 'radiation oncology' named entity 'Lombardy' named entity 'prognosis' named entity 'COVID-19' named entity 'severe pneumonia' named entity 'Brescia University' named entity 'WHO' named entity 'radiotherapy' named entity 'RT-PCR' named entity 'Radiation Oncology' named entity 'radiotherapy' named entity 'radiotherapy' named entity 'infection' named entity 'RT-PCR' named entity 'COVID-19' named entity 'prospective cohort' named entity 'asymptomatic' named entity 'COVID-19' named entity 'COVID-19' named entity 'Eastern Cooperative Oncology Group' named entity '45 days' named entity 'RT-PCR' named entity 'medical records' named entity 'Radiation Oncology' named entity 'Differential diagnosis' named entity 'covid-19' named entity 'cardiovascular diseases' named entity 'SARS-Cov-2' named entity 'infection' named entity 'radiation oncology' named entity 'triage' named entity 'Stage III' named entity 'radiation therapy' named entity 'respiratory symptoms' named entity 'off-label' named entity 'RT-PCR' named entity 'Lombardy' named entity 'SARS-Cov-2' named entity 'Brescia' named entity 'March 24' named entity 'Non-Small Cell Lung Cancer' named entity 'Intensive Care Unit' named entity 'radiotherapy' named entity 'sitrep' named entity 'infection' named entity 'invasive ventilation' named entity 'COVID-19 pandemic' named entity 'asymptomatic' named entity 'brachytherapy' named entity 'incubation time' named entity 'infection' named entity 'SARS-Cov-2' named entity 'RT-PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software